The EGFR family of type I growth factor receptor tyrosine kinases includes EGFR (HER1), c-erbB2 (HER2; neu), c-erbB3 (HER3) and c-erbB4 (HER4). c-erbB4 is involved in cell growth regulation and its expression or function may be altered in human cancers.
| Inventor | Institute |
|---|---|
| Bill Gullick | Imperial Cancer Research Fund |
| Cat. #: | 151215 |
|---|---|
| Tool sub type: | Primary antibody |
| Unit size: | 100 ug |
| Research Fields: | Cancer;Cell biology;Cell signaling and signal transduction |
| Application: | FACS ; IHC ; IF ; IP ; WB |
| Target: | ErbB4 (Her4, p180erbB4) |
| Reactivity: | Human ; Mouse |
| Clone: | HFR1 |
| Host: | Mouse |
| Class: | Monoclonal |
| Product description: | The EGFR family of type I growth factor receptor tyrosine kinases includes EGFR (HER1), c-erbB2 (HER2; neu), c-erbB3 (HER3) and c-erbB4 (HER4). c-erbB4 is involved in cell growth regulation and its expression or function may be altered in human cancers. |
|---|---|
| Conjugation: | Unconjugated |
| Isotype: | IgG2b |
| Immunogen: | Synthetic peptide sequence RSTLQHPDYLQEYST from the cytoplasmic domain of the protein (residues 1249-1264.) |
| Myeloma used: | Sp2/0-Ag14 |
| Target background: | The EGFR family of type I growth factor receptor tyrosine kinases includes EGFR (HER1), c-erbB2 (HER2; neu), c-erbB3 (HER3) and c-erbB4 (HER4). c-erbB4 is involved in cell growth regulation and its expression or function may be altered in human cancers. |
|---|
| Format: | Liquid |
|---|---|
| Concentration: | 1 mg/ml |
| Storage buffer: | PBS with 0.02% azide |
| Storage conditions: | -15° C to -25° C |
| Shipping conditions: | Dry ice |
| References: |
Cystatin M loss is associated with the losses of estrogen receptor, progesterone receptor, and HER4 in invasive breast cancer. Ko et al. 2010. Breast Cancer Res. 12(6):R100. PMID: 21092257. Gulati et al. 2010. Diagn Pathol. 5:18. PMID: 20331873. Overexpression of c-erbB2 is a negative prognostic factor in anaplastic astrocytomas. Sundvall et al. 2007. Oncogene. 26(48):6905-14. PMID: 17486069. Differential nuclear localization and kinase activity of alternative ErbB4 intracellular domains. Carn et al. 2005. Mol Cancer Ther. 4(2):243-55. PMID: 15713896. H-RAS V12-induced radioresistance in HCT116 colon carcinoma cells is heregulin dependent. Srinivasan et al. 1998. J Pathol. 185(3):236-45. PMID: 9771476. Expression of the c-erbB-4/HER4 protein and mRNA in normal human fetal and adult tissues and in a survey of nine solid tumour types. |
|---|
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151023 | Anti-IL12 [1-1D5] |
Key Info
Anti-IL12 [1-1D5]
|
View Tool | |||||||||||||||||||
| 151027 | Anti-HSVICP8 [10A3] |
Key Info
Anti-HSVICP8 [10A3]
|
View Tool | |||||||||||||||||||
| 151036 | Anti-ICAM1 [15.2] |
Key Info
Anti-ICAM1 [15.2]
|
View Tool | |||||||||||||||||||
| 151037 | Anti-Cdk1 [17 (A17)] |
Key Info
Anti-Cdk1 [17 (A17)]
|
View Tool | |||||||||||||||||||
| 151017 | Anti-MBP [R29.6] |
Key Info
Anti-MBP [R29.6]
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.